These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11253 related articles for article (PubMed ID: 10928381)

  • 1. PET imaging in oncology.
    Bar-Shalom R; Valdivia AY; Blaufox MD
    Semin Nucl Med; 2000 Jul; 30(3):150-85. PubMed ID: 10928381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Positron-emission tomography in oncology].
    Zaplatnikov K; Menzel C; Döbert N; Diehl M; Hamscho N; Grünwald F
    Klin Med (Mosk); 2003; 81(12):13-21. PubMed ID: 14971150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of (18)F-FDG in oncology.
    Nabi HA; Zubeldia JM
    J Nucl Med Technol; 2002 Mar; 30(1):3-9; quiz 10-1. PubMed ID: 11948260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG imaging.
    Coleman RE
    Nucl Med Biol; 2000 Oct; 27(7):689-90. PubMed ID: 11091113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
    Giorgetti A; Volterrani D; Mariani G
    Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A proposal for the rational use of the PET in oncology].
    Borrego Dorado I; Vázquez Albertino R
    Rev Esp Med Nucl; 2002 May; 21(3):163-73. PubMed ID: 12206749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 18F-FDG PET in evaluating cancers of lung.
    Acker MR; Burrell SC
    J Nucl Med Technol; 2005 Jun; 33(2):69-74; quiz 75-7. PubMed ID: 15930019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
    Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
    Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
    Czech N; Brenner W; Kampen WU; Henze E
    Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 563.